By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit

Key Statistics

Ownership: Public

Web Site: Idera Pharmaceuticals, Inc.
Symbol: IDRA

Company News
Idera Pharmaceuticals, Inc. (IDRA) To Be Added To The Russell 3000® And Russell 2000#0174; Indexes 6/27/2014 9:34:49 AM
Idera Pharmaceuticals, Inc. (IDRA) To Participate In A Panel Discussion At The Piper Jaffray Genomerx Symposium 6/17/2014 1:23:06 PM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Nucleic Acid Summit 2014 6/16/2014 8:58:38 AM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/28/2014 7:40:17 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy 5/13/2014 7:28:21 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Agreement With Abbott Laboratories (ABT) To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-Cell Lymphoma 5/8/2014 11:57:28 AM
Idera Pharmaceuticals, Inc. (IDRA) To Host Conference Call And Webcast To Report First Quarter 2014 Financial Results And Provide A Detailed Pipeline Review 5/6/2014 7:39:43 AM
Idera Pharmaceuticals, Inc. (IDRA) Expands Management Team with Three Key Hires 5/5/2014 6:57:23 AM
Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data at American Association for Cancer Research Showing IMO-8400 Inhibits Tumor Growth And Survival Signaling In B-Cell Lymphoma Cells With Oncogenic MYD88 L265P Mutation 4/8/2014 7:25:35 AM
Idera Pharmaceuticals, Inc. (IDRA)'s IMO-8400 Safe, Well Tolerated In Phase 2 Skin Disease Study 3/28/2014 6:40:21 AM